Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd. announced a change in the shareholding interests of its director, Jane Bell, who acquired additional shares and options in the company. This move may signal confidence in Amplia’s ongoing development of Focal Adhesion Kinase inhibitors, which are gaining traction in cancer and fibrosis treatment. Investors might view this as a positive indicator for the company’s future prospects in the pharmaceutical sector.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.